医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioCision to Showcase ThawSTAR CB Thawing System for Cryobags at ISCT 2016

2016年05月18日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN RAFAEL, Calif.

BioCision, LLC, a life science research and development company that standardizes processes from research through point-of-care, announced today that they will be showcasing their new ThawSTAR® CB Cryobag Thawing System at the International Society for Cellular Therapy (ISCT) 2016 annual meeting in Singapore.

The newest addition to BioCision’s Automated Cell Thawing Systems, the ThawSTAR CB automatically thaws cryobags commonly used to freeze, store and deliver larger volume cell-based therapeutics. The ThawSTAR CB System will reduce handling risks, eliminate the need for a water bath, and standardize thawing for consistent, reproducible results.

“The ThawSTAR CB System is a novel instrument that automates, and most importantly, de-risks bag thawing from manufacturing to point-of-care,” said Rolf O. Ehrhardt, MD, PhD, BioCision CEO. “Until recently, controlled thawing of a vial or bag was a frequently overlooked step in the cold chain. The ThawSTAR system allows our customers to improve the overall handling of cell therapies and further standardize this critical ‘last mile’ process.”

Features of the ThawSTAR CB System include:

  • Able to thaw a range of fill volumes (~50 to 250 ml) through smart load detection
  • Bag temperature monitoring at multiple positions
  • Connectivity with chain-of-custody solutions
  • Compatible with a broad range of bag models
  • Software interface for process customization and thawing operations
  • Integrated scanner for bag barcodes
  • Dry thawing without liquids or gels

Those interested in an overview of the ThawSTAR CB System are encouraged to stop by booth B19 during ISCT May 25-28, 2016. ThawSTAR CB will be commercially available in Q4 2016.

About BioCision, LLC

BioCision is a life science research and development company that provides tools to standardize critical processes throughout the healthcare industry. BioCision’s award-winning portfolio of translational products can be integrated throughout research, development and manufacturing workflows, enabling consistent temperature control for sensitive therapeutics and biological samples. By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development, and enable effective care delivery.

For more information visit http://www.biocision.com, or visit the BioCision blog for news and expert insight at http://www.biocision.com/blog/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160518005285/en/

CONTACT

BioCision:
Marla Kertzman, 209-852-9027
mkertzman@biocision.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果